You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Bortezomib and thalidomide for the first‑line treatment of multiple myeloma

  • Technology appraisal guidance
  • Reference number: TA228
  • Published:  27 July 2011
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Multiple myeloma (first line) - bortezomib and thalidomide: response to scrutiny letter

Multiple myeloma (first line) - bortezomib and thalidomide: response to scrutiny letter Multiple myeloma (first line) - bortezomib and thalidomide: response to scrutiny letter
15 November 2010
(187.11 Kb 54 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 16 December 2010

Back to top